G-CSFバイオシミラー販売市場：タイプ、用途、流通チャネル、地域別、2026～2032年

G-CSFバイオシミラー販売市場～2026～2032年

G-CSFバイオシミラー販売市場は、参照用生物製剤の特許切れ、がん罹患率の増加、費用対効果の高い治療オプションに対する需要の高まりなどを背景に力強い成長を遂げています。開発はさらに、有利な規制枠組み、ヘルスケアインフラの改善、市場と先進国市場の両方におけるバイオシミラーの採用増加によって支えられています。これにより、市場規模は2024年に118億6,000万米ドルを突破し、2032年には220億3,000万米ドルに達するとみられます。

こうした成長要因に加え、市場は製造プロセスや製品開発を強化するための研究開発投資の増加を目の当たりにしています。手頃な価格の生物学的治療への患者アクセスの改善に重点が置かれ、ヘルスケア提供者の間でバイオシミラーが受け入れられつつあることが、市場拡大の新たな道を開いています。さらに、世界中の医療制度が金額ベースのヘルスケアとコスト抑制戦略を重視するようになっていることも、地域別市場の成長を後押ししています。バイオシミラーに対する需要の高まりにより、市場は2026～2032年にかけてCAGR 8.88%で成長します。

世界のG-CSFバイオシミラー販売市場定義/概要

G-CSFバイオシミラーとは、化学療法を受けている患者や重度の好中球減少症の患者の白血球産生を刺激するために使用される、基準顆粒球コロニー刺激因子と類似性の高い生物製剤です。これらのバイオシミラー医薬品は、包括的な比較検査を通じて、参照製品と同等の品質、安全性、有効性を実証しています。

G-CSFバイオシミラーの開発と製造には、先進的バイオテクノロジープロセスと厳格な品質管理が必要です。各製品は、参照製品との治療上の同等性を保証すると同時に、ヘルスケアシステムと患者にコスト面での利点を提供するため、広範な特性評価と臨床検査を受けます。

G-CSFバイオシミラー販売市場の将来の展望は有望であり、新たな技術や用途における成長の可能性があります。製造プロセスの高度化、地域間の規制調和の進展、新規ドラッグデリバリーシステムの開発により、新たな開発が期待されます。適応症拡大の可能性と個別化医療への注目の高まりは、より多様で効果的な市場提供につながる可能性があります。

がん負担の増加はG-CSFバイオシミラー販売市場の成長をどのように促進するか？

世界のがん罹患率の上昇が、G-CSFバイオシミラー販売市場の成長を大きく後押ししています。がんの罹患率が世界中で上昇を続ける中、化学療法による好中球減少症を管理するためのG-CSF製剤を含む支持療法治療に対する需要が急増しています。このセグメントは、患者の転帰を改善し、化学療法の最適な投与スケジュールを促進するために極めて重要です。費用対効果の高いバイオシミラー製剤が利用可能になったことで、特にヘルスケア資源が限られている地域では、こうした重要な治療がより多くの患者にとって利用しやすくなりました。さらに、バイオシミラーの開発と製造プロセスの進歩により、コスト面での優位性を維持しながら製品の品質が向上しており、市場の魅力につながっています。バイオシミラーの有効性と安全性に関する医療従事者の意識の高まりも、市場の拡大を後押ししています。その結果、G-CSFバイオシミラー販売市場は、がん患者の増加、効果的な支持療法の必要性、バイオシミラー技術の継続的な改善やヘルスケアコミュニティにおける教育などの要因が重なり、力強い成長を遂げています。

複雑な製造プロセスという課題は、G-CSFバイオシミラー販売市場の成長にどのような影響を与えていますか？

製造プロセスの複雑さは、G-CSFバイオシミラー販売市場の成長に大きな影響を与える課題となっています。バイオシミラーの製造には、洗練された施設、先進的技術、熟練した人材が必要であり、多額の投資が必要となります。さらに、異なる製造バッチ間で一貫した製品品質を維持し、規制基準を満たすことは、製造業者にとって継続的な課題となっています。このような状況は、市場に参入する中小企業にとって特に困難であり、リソースの制約や技術的なハードルに遭遇して能力が制限されることが多いからです。さらに、製品の品質と法規制への準拠がますます重視されるようになり、製造の複雑さとコストが増しています。こうした課題に対処するため、産業は、製品の品質を維持しながら効率を高め、製造コストを削減できる、先進的製造技術とプロセスの最適化に投資しています。これらの取り組みは、よりサステイナブル生産環境を構築し、G-CSFバイオシミラー販売市場の競合情勢において既存と新規の参入企業がともに繁栄できるようにすることを目的としており、同時に、必要とする患者への高品質な治療へのアクセスを保証するものです。

目次

第1章 世界のg-CSFバイオシミラー販売市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のG-CSFバイオシミラー販売市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 G-CSFバイオシミラー販売の世界市場：タイプ別

• 概要
• 短時間作用型G-CSF
• 長時間作用型G-CSF

第6章 G-CSFバイオシミラー販売の世界市場：用途別

• 概要
• 血液疾患
• 腫瘍疾患
• 慢性疾患
• その他（急性放射線症候群）

第7章 G-CSFバイオシミラー販売の世界市場：流通チャネル

• 概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他（専門クリニック）

第8章 G-CSFバイオシミラー販売の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のG-CSFバイオシミラー販売市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• Sandoz（Novartis）
• Teva Pharmaceutical Industries
• Amgen Inc.
• Reddy's Laboratories
• Coherus BioSciences
• Biocon
• Intas Pharmaceuticals
• Mylan N.V.（Now Viatris）
• Kashiv BioSciences
• AbbVie

第11章 付録

• 関連調査

G-CSF Biosimilars Sales Market- 2026-2032

The G-CSF Biosimilars Sales Market is experiencing robust growth driven by patent expirations of reference biologics, increasing cancer incidence rates, and growing demand for cost-effective treatment options. The market expansion is further supported by favorable regulatory frameworks, improving healthcare infrastructure, and rising adoption of biosimilars in both developed and emerging markets. This is likely to enable the market size to surpass USD 11.86 Billion valued in 2024 to reach a valuation of around USD 22.03 Billion by 2032.

In addition to these growth factors, the market is witnessing increased investment in research and development for enhanced manufacturing processes and product development. The focus on improving patient access to affordable biological treatments and the rising acceptance of biosimilars among healthcare providers is opening new avenues for market expansion. Moreover, the growing emphasis on value-based healthcare and cost containment strategies by healthcare systems worldwide is driving regional market growth. The rising demand for biosimilars is enabling the market to grow at a CAGR of 8.88% from 2026 to 2032.

Global G-CSF Biosimilars Sales Market: Definition/Overview

G-CSF biosimilars are biologic medical products that are highly similar to reference granulocyte colony-stimulating factors used to stimulate the production of white blood cells in patients undergoing chemotherapy or those with severe neutropenia. These biosimilars have demonstrated comparable quality, safety, and efficacy to their reference products through comprehensive comparative studies.

The development and manufacturing of G-CSF biosimilars involve sophisticated biotechnology processes and stringent quality controls. Each product undergoes extensive characterization and clinical testing to ensure therapeutic equivalence to the reference product while offering cost advantages to healthcare systems and patients.

The future scope of the G-CSF biosimilars market is promising, with potential for growth in emerging technologies and applications. Advancements in manufacturing processes, increasing regulatory harmonization across regions, and the development of novel drug delivery systems are expected to open new market opportunities. The potential for expanding indications and the growing focus on personalized medicine may lead to more diverse and effective market offerings.

How does the Increasing Cancer Burden Drive the Growth of The G-CSF Biosimilars Market?

The rising global cancer burden significantly drives growth in the G-CSF Biosimilars Market. As cancer incidence rates continue to escalate worldwide, the demand for supportive care treatments, including G-CSF products for managing chemotherapy-induced neutropenia, has surged. This segment is crucial for improving patient outcomes and facilitating optimal chemotherapy dosing schedules. The availability of cost-effective biosimilar alternatives has made these essential treatments more accessible to a broader patient population, especially in regions with limited healthcare resources. Furthermore, advancements in biosimilar development and manufacturing processes have improved product quality while retaining cost advantages, contributing to their attractiveness in the market. The increasing awareness among healthcare providers regarding the efficacy and safety of biosimilars is also fostering market expansion. As a result, the G-CSF biosimilars market is witnessing robust growth, driven by a combination of factors such as rising cancer cases, the need for effective supportive care, and continuous improvements in biosimilar technology and education within the healthcare community.

How is the Challenge of Complex Manufacturing Processes Impacting the Growth of The G-CSF Biosimilars Market?

The complexity of manufacturing processes poses a significant challenge impacting the growth of the G-CSF Biosimilars Market. Producing biosimilars necessitates sophisticated facilities, advanced technology, and highly skilled personnel, leading to substantial investment requirements. Additionally, maintaining consistent product quality and meeting regulatory standards across different manufacturing batches presents ongoing challenges for manufacturers. This situation is particularly difficult for smaller companies entering the market, as they often encounter resource constraints and technical hurdles that limit their capabilities. Furthermore, the increasing emphasis on product quality and regulatory compliance adds to the complexities and costs of manufacturing. To address these challenges, the industry is investing in advanced manufacturing technologies and process optimization, which can enhance efficiency and reduce production costs while maintaining product quality. These initiatives aim to create a more sustainable production environment, enabling both established and new players to thrive in the competitive landscape of the G-CSF biosimilars market while ensuring access to high-quality treatments for patients in need.

Category-wise Acumens

How will the Dominance of Long-acting G-CSF Drive the Growth of the Type Segment?

Long-acting G-CSF's dominance in the Type segment is significantly driving growth in the overall biosimilars market. The improved patient compliance, reduced administration frequency, and enhanced therapeutic outcomes associated with long-acting formulations position them as the preferred choice among healthcare providers and patients. These formulations benefit from established clinical evidence and widespread acceptance in various treatment protocols, reinforcing their market presence.

Continued innovation in drug delivery systems and improved pharmacokinetic profiles further fuels the market leadership of long-acting G-CSF. The development of new formulations and administration devices has successfully expanded the patient base and improved treatment adherence. Additionally, the convenience of administration and fewer hospital visits contribute to its success, particularly in ambulatory care settings. As manufacturing technology advances and patient preferences evolve, the long-acting segment is expected to maintain its growth momentum through ongoing product innovation and strategic market expansion. This focus on enhancing patient experience and treatment outcomes will be pivotal in sustaining the long-acting G-CSF segment's leadership in the biosimilars market.

How will the Growing Importance of Hospital Pharmacies Drive the Expansion of The Distribution Channel Segment?

The dominance of hospital pharmacies in G-CSF biosimilar distribution highlights the critical role of institutional healthcare providers in managing complex biological treatments. Hospital pharmacies are equipped with specialized storage facilities, trained personnel, and integrated care coordination essential for handling biological products. This capability is particularly vital for maintaining product integrity and ensuring proper administration.

Additionally, hospital pharmacies enable direct interaction between healthcare providers and patients, allowing for better monitoring and management of treatment outcomes. Their ability to provide comprehensive patient care while adhering to cold chain requirements makes hospital pharmacies an ideal distribution channel for G-CSF biosimilars. Consequently, we can anticipate increased investment in hospital pharmacy infrastructure and staff training to improve the efficiency of biological product handling. Innovations in inventory management systems and patient care coordination within the hospital pharmacy segment will facilitate more effective distribution and utilization of G-CSF biosimilars. This focus on enhancing hospital pharmacy capabilities is essential for ensuring that patients receive high-quality care and access to necessary treatments

Country/Region-wise Acumens

Will the Advanced Healthcare Infrastructure Drive the Dominance of North America in The G-CSF Biosimilars Market?

The dominance of North America in the G-CSF biosimilars sales market is significantly driven by its advanced healthcare infrastructure and robust regulatory framework. The region's early adoption of biosimilars, bolstered by favorable reimbursement policies and healthcare cost containment initiatives, has established a strong market foundation. This favorable context is enhanced by high awareness among healthcare providers and patients regarding the benefits of biosimilars. North America's leadership in oncology treatment and supportive care has further solidified its position in the G-CSF biosimilars market. The region's substantial investment in healthcare technology and a strong emphasis on evidence-based medicine have facilitated broader acceptance of biosimilar products. Additionally, the presence of major pharmaceutical companies and research institutions fosters continuous innovation and market growth, ensuring North America remains a key market for G-CSF biosimilar manufacturers and developers. As the market evolves, ongoing collaborations and advancements in biosimilar development are expected to reinforce North America's dominant position in the global G-CSF biosimilars landscape.

Will the Growing Healthcare Access Drive the Expansion of The G-CSF Biosimilars Market in Asia-Pacific?

The rapidly improving healthcare access in the Asia-Pacific region is a key driver of expansion in the G-CSF Biosimilars sales Market, presenting significant growth opportunities. With large patient populations and increasing healthcare investments, countries like China, India, and Japan are witnessing substantial growth in biosimilar adoption. This trend is fueled by government initiatives aimed at improving healthcare accessibility, rising healthcare expenditure, and growing insurance coverage. As healthcare systems expand, the demand for cost-effective biological treatments increases, enhancing opportunities for biosimilar manufacturers. The region's evolving regulatory landscape, where authorities are establishing clearer pathways for biosimilar approval, further propels this growth. Innovations in local manufacturing capabilities, coupled with strategic partnerships between global and regional players, are accelerating market development. This collaborative environment is establishing the Asia-Pacific region as a crucial market for G-CSF biosimilar manufacturers. Furthermore, as awareness of biosimilars grows among healthcare providers and patients, the region is poised for continued expansion in the biosimilars sector, reflecting a shift towards sustainable healthcare solutions.

Competitive Landscape

The G-CSF biosimilars sales market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the G-CSF biosimilars sales market include:

Sandoz (Novartis)

Pfizer Inc.

Teva Pharmaceutical Industries

Amgen Inc.

Reddy's Laboratories

Coherus BioSciences

Biocon

Intas Pharmaceuticals

Mylan N.V. (Now Viatris)

Kashiv BioSciences

Latest Development

G-CSF Biosimilars Market, By Category

• Type:
• Short-acting G-CSF
• Long-acting G-CSF
• Application:
• Oncology
• Blood Disorders
• Chronic Diseases
• Others (Acute Radiation Syndrome)
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others (Specialty Clinics)
• Region:
• North America
• Europe
• Asia-Pacific
• Middle East & Africa
• Latin America

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL G-CSF BIOSIMILARS SALES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL G-CSF BIOSIMILARS SALES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY TYPE

• 5.1 Overview
• 5.2 Short-acting G-CSF
• 5.3 Long-acting G-CSF

6 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Blood Disorders
• 6.3 Oncology Diseases
• 6.4 Chronic Diseases
• 6.5 Others (Acute Radiation Syndrome)

7 GLOBAL G-CSF BIOSIMILARS SALES MARKET, DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Pharmacies
• 7.5 Others (Specialty Clinics)

8 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL G-CSF BIOSIMILARS SALES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Sandoz (Novartis)
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Teva Pharmaceutical Industries
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Amgen Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Reddy's Laboratories
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Coherus BioSciences
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Biocon
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Intas Pharmaceuticals
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Mylan N.V. (Now Viatris)
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Kashiv BioSciences
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 AbbVie
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research